| Abstrakt: |
A recent study conducted by the Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS) in Barcelona, Spain, explores the use of chimeric HLA antibody receptor T cell therapy for humoral transplant rejection. Antibody-mediated rejection (ABMR) is a significant challenge in solid organ transplantation, and current treatments are not effective. The researchers genetically engineered chimeric HLA-antibody receptor (CHAR) T cells to target B cells that produce donor-specific HLA antibodies, which are central to ABMR. This technology shows promise as a selective desensitization protocol and treatment for antibody-mediated rejection after organ transplantation. [Extracted from the article] |
